U.S. Markets close in 1 hr 45 mins

Valneva SE (VALN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
11.56+0.17 (+1.49%)
As of 01:35PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close11.39
Bid11.53 x 1100
Ask11.86 x 1100
Day's Range11.51 - 11.72
52 Week Range9.07 - 17.05
Avg. Volume7,042
Market Cap802.194M
Beta (5Y Monthly)0.94
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VALN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Valneva SE
    Daily – Vickers Top Buyers & Sellers for 06/05/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    6 months agoArgus Research
View more
  • Insider Monkey

    Valneva SE (NASDAQ:VALN) Q3 2023 Earnings Call Transcript

    Valneva SE (NASDAQ:VALN) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Good day and thank you for standing by. Welcome to the Valneva 9 Months 2023 Financial Results Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today, Joshua Drumm, VP, Investor Relations. Please go ahead. Joshua Drumm: […]

  • BioPharma Dive

    Valneva’s chikungunya vaccine approved by FDA

    The preventive shot is the first to receive regulatory approval for the mosquito-borne illness, which is growing in prevalence worldwide.

  • Reuters

    FDA finds no misconduct at trial sites for Pfizer's Lyme disease shot- Care Access

    The U.S. health regulator did not find any misconduct at clinical sites managed by Care Access for Pfizer and French partner Valneva's trial of a Lyme disease vaccine candidate, the contract research firm said on Wednesday. Pfizer and Valneva said in February they will stop testing the vaccine in roughly half of U.S. patients in a late-stage study, due to a breach of clinical trial guidelines by a third-party contractor. The vaccine for Lyme disease, which causes infections that are transmitted to humans through ticks, has shown a "strong immune response" in a mid-stage study in both children and adolescents a month after a booster dose.